Early detection of diseases is crucial to ensure timely treatment and avoid severe outcomes. To address this, we developed CHELO (Chip + E. coli + Lpp-OmpA), a device capable of detecting multiple diseases using biosensors. We focused on Leukemia, where hematopoietic stem cells abnormally proliferate, affecting the patient's health. Each year, around 29,000 adults and 2,000 children are diagnosed with leukemia, with acute cases progressing rapidly and requiring early detection. Our project identifies biomarkers for Acute Myeloid Leukemia (AML) using our model, Artemis' Eye. We discovered CD97 as a key biomarker and designed short peptides that bind to it. These peptides are expressed on our engineered E. coli, BELO (BL21 + E. coli + Lpp-OmpA). When CD97 binds to these peptides, BELO emits an electrical signal, indicating detection. This system alerts users to potential disease risks, enabling prompt medical attention. In the future, we aim to optimize the peptides, broaden disease detection, and enhance accuracy, helping patients worldwide receive timely treatment.

To see more infromation, please start at the Description page.